Drug Trial Radar · NCT03065062
Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors
Last checked: Nov 19, 2026Latest source record: Feb 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Suspended
Enrollment
75
Planned (sponsor's estimate)
Start
Feb 28, 2017
Primary completion
Dec 31, 2026
Study completion Jan 31, 2027
Sponsor
- Lead sponsor
- Dana-Farber Cancer InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Pfizer
- First posted
- Feb 27, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This research study is studying a combination of drugs as a possible treatment for cancer that might have a specific change in the phosphatidylinositol-3 phosphate (PI3K) pathway.
Conditions
- Lung Cancer Squamous Cell
- Solid Tumors
- Head & Neck Cancer
- Pancreatic Cancer
Interventions
PalbociclibDrug
Palbociclib will be administered orally once daily, 3 weeks out of every 4 in each cycle. The initial dose for part 1 of the study will be 100 mg daily. Dosing will be adjusted until Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) are established. No pre-medications for palbociclib are required. It should be administered with food.
GedatolisibDrug
Gedatolisib will be administered once weekly on the first day for each of the four weeks during the 4-week cycle. The initial dose for part 1 of the study will be 110 mg. Dosing will be adjusted until Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) are established. No pre-medications for gedatolisib are required.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Tolerated Dose and Recommended Phase 2 DoseTime frame: 2 years
- Incidence of Treatment-Emergent Adverse EventsTime frame: 2 years
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Massachusetts General Hospital
Boston, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.